Quantcast

Reportlinker Adds Pulmonary Drug Delivery Technologies – A Global Market Perspective

November 18, 2009

NEW YORK, Nov. 18 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Pulmonary Drug Delivery Technologies – A Global Market Perspective

http://www.reportlinker.com/p0164238/Pulmonary-Drug-Delivery-Technologies—A-Global-Market-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Until recent years, respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease represented the sole therapeutic areas of the pulmonary sector. However, recent technological advancements have spanned the application of pulmonary devices to the treatment of non-respiratory conditions such diabetes, migraine. The attractiveness of pulmonary delivery of drugs for the treatment of respiratory diseases stems from the fact that topical drug deposition to infected lung gives a fast therapeutic effect and reduces side effects associated with key drugs.

Advancements in formulating technology are expected to push sales of dry powder inhalers replacing metered-dose inhalers to a larger extent. Dry powder inhalation (DPI), an enabling concept in the noninvasive drug delivery, is progressively emerging as important contender among pulmonary drug delivery methods. This importance is being fueled by latest developments including sophisticated device architectures, growing research activity in powder formulations, and innovations in particle engineering.

These and other market data and trends are presented in “Pulmonary Drug Delivery Technologies: A Global Market Perspective” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

PULMONARY DRUG DELIVERY TECHNOLOGIES BMR-1038

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. MARKET DYNAMICS 4

Market Overview 4

Pulmonary Devices: Gaining Pace 4

Market Highlights 4

Primary Position of the US 5

Pulmonary Drug Delivery: An Attractive Non-Invasive Option 5

Chief Pulmonary Delivery Technologies 6

Most Effective Route for Respiratory Syndromes 6

Leading Inhalation Prescription Drugs Across All Segments 7

The Attractiveness of Inhalers 7

Choice of Drug Delivery System 7

Inhalation Therapy: A Retrospection 7

Pulmonary Drug Delivery – Market Snapshots 8

3. TRENDS AND ISSUES 9

Market Snippets 9

Focus of New Age Pulmonary Devices 9

Dry Powder Inhalation: A Promising Technology 9

Research Activities in Inhaled Drug Delivery 10

Lung Versus Oropharyngeal Deposition: A Major Challenge 10

Competitive Environment 10

A Backdrop 10

Market Leaders 11

Industry Efforts 12

Inefficient Use of Pulmonary Drug Delivery Systems 12

MDIs 12

Spacers 12

Dry Powder Inhalers 13

Issues Facing Various Inhalation Devices 13

Jet Nebulizers 13

MDIs 13

DPIs 14

4. GROWTH DRIVERS 14

Growth Drivers in Pulmonary Drug Delivery 14

Use of Nanotechnology in Drug Delivery Products 14

Other Growth Areas 14

Innovative Pulmonary Devices Shape Progress 15

Pulmonary Insulin 15

Alternative Drug Delivery Systems: A Review 16

Market Size 16

Inhaled Small Molecule Therapeutics 16

5. PRODUCT FACTS 16

Metered Dose Inhalers (MDIs) 17

Dry Powder Inhalers (DPIs) 17

Nebulizers 17

6. REGULATORY ENVIRONMENT 17

The Montreal Protocol 17

FDA Bans the Use of CFC’s in Metered Dose Inhalers 18

7. CORPORATE DEVELOPMENTS 18

Sepracor Signs Agreement with Nycomed 18

Kamada Enter into Strategic Pacts with Pari Pharma 18

GlaxoSmithKline Ties-Up with Amira Pharmaceuticals 19

Consort Medical Releases Meter Dose Inhalers 19

Trinity Chiesi Pharmaceuticals Introduces Fostair 19

BattellePharma Takes Over Ventaira Pharmaceuticals 19

Eurand Takes Over SourceCF 20

Aradigm Signs Agreement with Lung Rx for Developing AERx

Essence(R)- Technology 20

Vectura Inks Agreement with a European Company 20

ZYFLO CR(TM) Obtains FDA Clearance 21

SkyePharma Revises Agreement with Abott 21

Alnylam Presents Scientific Progress of ALN-RSV01 21

Bayer HealthCare and Nektar Therapeutics to Develop NKTR-061 21

AstraZeneca Launches Symbicort® 22

Dey, L.P Unveils Perforomist(TM) 22

Next Safety Rolls Out Hi-Performance Drug Delivery Technology 22

8. MAJOR PLAYERS 23

3M Drug Delivery Systems Division (USA) 23

Akela Pharma Inc (Canada) 23

Alkermes, Inc. (USA) 23

Aradigm Corporation (USA) 23

AstraZeneca Plc (UK) 23

Baxter Healthcare Corporation (USA) 24

Chiesi Farmaceutici SpA (Italy) 24

Consort Medical Plc (UK) 24

Dey L.P. (USA) 24

GlaxoSmithKline Plc (UK) 24

Graceway Pharmaceuticals, LLC (USA) 25

Nektar Therapeutics (USA) 25

Oriel Therapeutics, Inc. (USA) 25

Sepracor, Inc. (USA) 25

SkyePharma Plc (UK) 25

Vectura Group Plc (UK) 26

9. GLOBAL MARKET ANALYTICS 26

10. THE UNITED STATES 30

Forecast for the Near Future 30

Nebulizers: Engraving High Market Interests 31

New Age Pulmonary Drug Delivery Technologies 31

Ranking of Inhaled Prescription Drugs in the US 32

Role of FDA 32

Metered Dose Inhalers 32

Non-CFC Metered Dose Inhalers 32

Dry Powder Inhalers 32

Popular DPIs in the US 33

Trends in DPI Devices 33

Drug Delivery Market in the US 34

Competitive Landscape 34

11. CANADA 36

12. JAPAN 37

Market Overview 37

Market Highlights 37

13. EUROPE 38

a. France 42

b. Germany 43

c. The United Kingdom 44

d. Italy 46

e. Spain 48

f. Russia 49

g. Rest of Europe 50

14. ASIA-PACIFIC 52

China 52

Market Scenario 52

India 52

Market Scenario 52

Dry Powder Inhalers for Children 53

Device Prices 53

Australia 53

Asthma: The Most Common Chronic Suffering Among Australians 53

Australia Finding Preventives for Asthma Cure 53

Use of CFCs in Australia 54

15. LATIN AMERICA 55

Brazil 55

16. REST OF WORLD 56

EXHIBITS

Table 1: Percentage Breakdown of Major Brands in the Global

Market for Inhaled Drug Delivery Systems – 2004

Table 2: Percentage Breakdown of World Market for Pulmonary

Drug Delivery Technologies by Drug Category – 2005

Table 3: Global Pulmonary Drug Delivery Technologies Market by

Region for the Period 2007-2015 (Sales in US$ Million)

Table 4: Percentage Breakdown of Global Pulmonary Drug

Delivery Technologies Market by Region for the Years 2008 &

2012

Table 5: Global Metered Dose Inhalers (MDIs) Market by Region

for the Period 2007-2015 (Sales in US$ Million)

Table 6: Percentage Breakdown of Global Metered Dose Inhalers

(MDIs) Market by Region for the Years 2008 & 2012

Table 7: Global Dry Powder Inhalers (DPIs) Market by Region

for the Period 2007-2015 (Sales in US$ Million)

Table 8: Percentage Breakdown of Global Dry Powder Inhalers

(DPIs) Market by Region for the Years 2008 & 2012

Table 9: Global Nebulizers Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 10: Percentage Breakdown of Global Nebulizers Market by

Region for the Years 2008 & 2012

Table 11: Percentage Breakdown of US Market for Pulmonary Drug

Delivery Technologies by Application Area – 2010P

Table 12: Percentage Breakdown of the Non-CFC Metered Dose

Inhalers Market by Application Areas in the US – 2010

Table 13: Percentage Breakdown of Non-CFC Metered Dose

Inhalers Primary Manufacturers in the US – 2004

Table 14: Percentage Breakdown of Leading Dry Powder Inhalers

Manufacturers in the US – 2004

Table 15: Percentage Breakdown of Dry Powder Inhalers by

Application Areas in the US – 2010

Table 16: Pulmonary Drug Delivery Technologies Market by

Product Segment in the US: 2007-2015 (Sales in US$ Million)

Table 17: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in the US for the Years

2008 & 2012

Table 18: Pulmonary Drug Delivery Technologies Market by

Product Segment in Canada: 2007-2015 (Sales in US$ Million)

Table 19: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Canada for the Years

2008 & 2012

Table 20: Percentage Breakdown of Leading Pulmonary Drug

Delivery Systems Brands in Japan – 2004

Table 21: Pulmonary Drug Delivery Technologies Market by

Product Segment in Japan: 2007-2015 (Sales in US$ Million)

Table 22: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Japan for the Years

2008 & 2012

Table 23: Pulmonary Drug Delivery Technologies Market by

Region in Europe: 2007-2015 (Sales in US$ Million)

Table 24: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Region in Europe for the Years 2008 &

2012

Table 25: Pulmonary Drug Delivery Technologies Market by

Product Segment in Europe: 2007-2015 (Sales in US$ Million)

Table 26: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Europe for the Years

2008 & 2012

Table 27: Pulmonary Drug Delivery Technologies Market by

Product Segment in France: 2007-2015 (Sales in US$ Million)

Table 28: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in France for the Years

2008 & 2012

Table 29: Pulmonary Drug Delivery Technologies Market by

Product Segment in Germany: 2007-2015 (Sales in US$ Million)

Table 30: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Germany for the

Years 2008 & 2012

Table 31: Percentage Breakdown of by Major Brands in the UK

Market for Inhaled Drug Delivery Systems – 2004

Table 32: Pulmonary Drug Delivery Technologies Market by

Product Segment in the UK: 2007-2015 (Sales in US$ Million)

Table 33: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in the UK for the Years

2008 & 2012

Table 34: Percentage Breakdown of Major Pulmonary Drug

Delivery Systems Brands in Italy – 2004

Table 35: Pulmonary Drug Delivery Technologies Market by

Product Segment in Italy: 2007-2015 (Sales in US$ Million)

Table 36: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Italy for the Years

2008 & 2012

Table 37: Percentage Breakdown of Leading Pulmonary Drug

Delivery Systems Brands in Spain – 2004

Table 38: Pulmonary Drug Delivery Technologies Market by

Product Segment in Spain: 2007-2015 (Sales in US$ Million)

Table 39: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Spain for the Years

2008 & 2012

Table 40: Pulmonary Drug Delivery Technologies Market by

Product Segment in Russia: 2007-2015 (Sales in US$ Million)

Table 41: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Russia for the Years

2008 & 2012

Table 42: Pulmonary Drug Delivery Technologies Market by

Product Segment in Rest of Europe: 2007-2015 (Sales in US$

Million)

Table 43: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Rest of Europe for

the Years 2008 & 2012

Table 44: Pulmonary Drug Delivery Technologies Market by

Product Segment in Asia-Pacific: 2007-2015 (Sales in US$

Million)

Table 45: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Asia-Pacific for the

Years 2008 & 2012

Table 46: Pulmonary Drug Delivery Technologies Market by

Product Segment in Latin America: 2007-2015 (Sales in US$

Million)

Table 47: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Latin America for

the Years 2008 & 2012

Table 48: Pulmonary Drug Delivery Technologies Market by

Product Segment in Rest of World: 2007-2015 (Sales in US$

Million)

Table 49: Percentage Breakdown of Pulmonary Drug Delivery

Technologies Market by Product Segment in Rest of World for

the Years 2008 & 2012

COMPANIES PROFILED

To order this report:

Pulmonary Drug Delivery Technologies – A Global Market Perspective

http://www.reportlinker.com/p0164238/Pulmonary-Drug-Delivery-Technologies—A-Global-Market-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Contact Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus